OmniAb Navigates Biotech Shifts: A Look at Growth, Innovation, and Future Prospects
Biotechnology firm OmniAb (OABI) recently released its fourth-quarter 2025 earnings, revealing a company adapting to a dynamic market. While full-year revenue dipped to $18.7 million from $26.4 million in 2024, the company is strategically positioning itself for future growth through technological innovation and a focus on operational efficiency. This analysis delves into the key takeaways from the earnings call and explores potential future trends for OmniAb and the broader antibody discovery landscape.
Strategic Partnerships Fuel Expansion
OmniAb’s partner network continues to expand, reaching 107 active partners by year-end. This growth reflects the increasing demand for its antibody discovery platforms. The company secured modern license agreements with institutions like Dana-Farber Cancer Institute and MabTherix Biosciences, alongside collaborations with two major global pharmaceutical firms. A majority of partners are based in the United States, with the remainder located in Europe and Asia.
Program Progression and Clinical Pipeline
The company boasts 407 active programs, a net increase of 44 during the year, with 84 new programs initiated. Twenty-five programs advanced across various development stages, including one reaching the registration phase and sixteen moving from discovery to preclinical development. Currently, 32 active clinical programs and approved products are leveraging OmniAb’s technology, representing over $350 million in remaining contracted milestone payments.
New Technologies Drive Innovation: OmniUltra and Exploration
OmniAb is investing heavily in innovative platforms to differentiate itself. The launch of OmniUltra, a transgenic chicken platform capable of expressing ultra-long CDRH3s, opens doors to peptide therapeutics. The Exploration platform, introduced mid-2025, provides partners with high-throughput single B-cell screening capabilities directly in their labs. Two units were deployed by year-end, with initial partner engagement proving positive.
Financial Performance and Outlook
Despite the revenue decrease in 2025, OmniAb reduced operating expenses to $87.6 million, down from $100.9 million in 2024, including a $3.9 million noncash impairment charge. The net loss was $64.8 million, or $0.57 per share. Looking ahead, the company projects revenue in the $25 million-$30 million range for 2026, with operating expenses between $80 million-$85 million. Cash operating expenses are expected to be $50 million-$55 million, with a year-end cash position of $30 million-$35 million.
Shifting Revenue Model: From Milestones to Royalties
OmniAb anticipates a transition from a milestone-based revenue model to a more royalty-driven one. Currently, over 98% of programs carry future contracted economics, with over $3 billion in total contracted milestone payments and an average royalty rate of 3.4%. This shift promises a more stable and predictable revenue stream.
Partner Pipeline Highlights
Several partner programs are poised for key milestones in 2026. Immunovant’s IMVT-1402 is expected to release top-line data from trials in rheumatoid arthritis and lupus. Teva’s TEV-‘408 is advancing with funding from Royalty Pharma, with Phase Ib trial results anticipated for vitiligo. Merck KGaA is moving M9140 to Phase III trials in metastatic colorectal cancer.
The Future of Antibody Discovery: Trends and Challenges
The Rise of Smaller Antibody Fragments
The industry is increasingly focused on smaller antibody fragments, like picobodies, which offer advantages in terms of tissue penetration and manufacturing. OmniUltra’s ability to generate these fragments positions OmniAb at the forefront of this trend.
Peptide Therapeutics: A Growing Market
The success of GLP-1 receptor agonists has fueled significant interest in peptide therapeutics. OmniUltra’s entry into this space provides a new avenue for growth and collaboration.
High-Throughput Screening and AI Integration
Platforms like OmniAb’s Exploration are leveraging machine learning and artificial intelligence to accelerate antibody discovery. This trend is expected to continue, driving down costs and increasing efficiency.
FAQ
Q: What is an OmniDAb?
A: OmniDAb is OmniAb’s single-domain antibody discovery platform for generating humanized antibody fragments.
Q: What is a CDRH3?
A: CDRH3 is the third complementarity-determining region of the antibody heavy chain, critical for antigen binding specificity and diversity.
Q: What is the Exploration platform?
A: Exploration is a high-throughput single B-cell screening platform that leverages machine learning and artificial intelligence.
Q: What is OmniAb’s 2026 revenue guidance?
A: OmniAb expects revenue in the $25 million-$30 million range for 2026.
Did you know? OmniAb has eight of the ten largest pharmaceutical companies in the world as active partners.
Pro Tip: Keep an eye on the progress of Immunovant’s IMVT-1402 and Teva’s TEV-‘408, as these programs represent significant potential catalysts for OmniAb’s royalty revenue.
Stay informed about OmniAb’s progress and the evolving antibody discovery landscape. Visit the OmniAb website to learn more and explore partnership opportunities.
